Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper’s first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. “Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
The Latest on: Liver diseases
via Google News
The Latest on: Liver diseases
- CRISPR edits lung-disease gene in utero, hitting only the affected organ in a mouse study on April 17, 2019 at 11:16 am
Although a key challenge of CRISPR is getting it to affected cells and organs while sparing healthy ones — to cure a liver disease, it doesn’t help to CRISPR heart cells — a fetus’ lungs literally ... […]
- CRISPR edits out a deadly lung disease in mice before birth on April 17, 2019 at 11:00 am
Peranteau previously co-led a Nature Medicine study that used CRISPR-Cas9 and base editing tools to treat mouse fetuses with a lethal genetic liver disease. For this study, the team showed that in ... […]
- Innate immune sensor responding to gut microbes can suppress liver cancer on April 16, 2019 at 11:33 pm
Major risk factors for HCC include hepatitis B or C viral infection, chronic alcohol abuse, and nonalcoholic fatty liver disease, a condition increasing worldwide along with obesity. Although the ... […]
- Genetic sequencing uncovers causes for mysterious liver disease in adults on April 16, 2019 at 6:36 am
In up to 30% of individuals with chronic liver disease, the cause is unknown. To test for possible genetic factors in such cases, Yale researchers conducted whole-exome sequencing for a small group of ... […]
- Gilead teams with startup to turn machine learning on fatty liver disease on April 16, 2019 at 4:51 am
Even before much of the world last year found out about Daphne Koller's machine-learning-driven drug development company, she was invited to speak to Gilead Sciences Inc. scientists. The ensuing ... […]
- Genetic analysis has potential to transform diagnosis and treatment of adults with liver disease of unknown cause on April 15, 2019 at 9:50 am
Adults suffering from liver disease of unknown cause represent an understudied and underserved patient population. A new study reported in the Journal of Hepatology, supports the incorporation of ... […]
- Lanreotide Makes Its Mark in Tx of Rare Liver Disease on April 13, 2019 at 12:10 pm
VIENNA -- Patients with polycystic kidney disease and polycystic liver disease randomized to treatment with lanreotide were associated with a reduction in liver volume compared to standard of care, a ... […]
- Nonalcoholic fatty liver disease found in large numbers of teenagers and young adults on April 13, 2019 at 3:16 am
12 April 2019, Vienna, Austria: A large population-based study in the UK has revealed new evidence that large numbers of young adults have features suggestive of nonalcoholic fatty liver disease ... […]
- Novo Nordisk and Gilead team up to test fatty liver disease treatment on April 12, 2019 at 9:20 am
COPENHAGEN, April 12 (Reuters) - Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease ... […]
- Can adding Novo's GLP-1 to Gilead's NASH combo help hit fatty liver disease? New trial aims to find out on April 12, 2019 at 2:50 am
After announcing a small but broadly positive combo for its two biotech buyout nonalcoholic steatohepatitis drugs at the International Liver Congress yesterday, Gilead is hoping that adding a diabetes ... […]
via Bing News